Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease
暂无分享,去创建一个
Carlos Cepeda | Michael S Levine | C. Cepeda | M. Levine | M. Hayden | B. Leavitt | D. Cummings | N. Bamford | J. A. Joyce | V. André | N. Wu | Jeffrey B Carroll | Michael R Hayden | J. Carroll | Véronique M André | Blair R Leavitt | Prasad R Joshi | Nan-Ping Wu | Damian M Cummings | John A Joyce | Nigel S Bamford | Prasad R. Joshi | Nanping Wu
[1] W. Betz,et al. Optical analysis of synaptic vesicle recycling at the frog neuromuscular junction. , 1992, Science.
[2] Hui Zhang,et al. Heterosynaptic Dopamine Neurotransmission Selects Sets of Corticostriatal Terminals , 2004, Neuron.
[3] C. Stevens,et al. Estimates for the pool size of releasable quanta at a single central synapse and for the time required to refill the pool. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] A. Young. Huntingtin in health and disease. , 2003, The Journal of clinical investigation.
[5] C. Cepeda,et al. Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.
[6] Carlos Cepeda,et al. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. , 2006, Journal of neurophysiology.
[7] R. Schneggenburger,et al. Presynaptic Capacitance Measurements and Ca2+ Uncaging Reveal Submillisecond Exocytosis Kinetics and Characterize the Ca2+ Sensitivity of Vesicle Pool Depletion at a Fast CNS Synapse , 2003, The Journal of Neuroscience.
[8] T. Sejnowski,et al. [Letters to nature] , 1996, Nature.
[9] A. Reiner,et al. Evidence for Differential Cortical Input to Direct Pathway versus Indirect Pathway Striatal Projection Neurons in Rats , 2004, The Journal of Neuroscience.
[10] M. Mayer,et al. Structural determinants of allosteric regulation in alternatively spliced AMPA receptors , 1995, Neuron.
[11] M. Hayden,et al. Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.
[12] A. Buisson,et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] G. Gerhardt,et al. Microdialysis studies of basal levels and stimulus-evoked overflow of dopamine and metabolites in the striatum of young and aged Fischer 344 rats , 1999, Brain Research.
[14] Stephen J. Smith,et al. The kinetics of synaptic vesicle recycling measured at single presynaptic boutons , 1993, Neuron.
[15] J. Penney,et al. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia , 1990, Annals of neurology.
[16] He Li,et al. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. , 2003, Human molecular genetics.
[17] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[18] L. Raymond,et al. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.
[19] S. Lipton,et al. Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.
[20] Charles J. Wilson,et al. Spontaneous subthreshold membrane potential fluctuations and action potential variability of rat corticostriatal and striatal neurons in vivo. , 1997, Journal of neurophysiology.
[21] Robert C. Malenka,et al. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.
[22] G. Gerhardt,et al. Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study. , 1999, The Journal of pharmacology and experimental therapeutics.
[23] John A Dani,et al. Selective Dopamine Filter of Glutamate Striatal Afferents , 2004, Neuron.
[24] R. Wightman,et al. Catecholamine exocytosis is diminished in R6/2 Huntington’s disease model mice , 2007, Journal of neurochemistry.
[25] Michael V. Johnston,et al. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development , 1990, Brain Research Reviews.
[26] K. Tóth,et al. Afferent-specific innervation of two distinct AMPA receptor subtypes on single hippocampal interneurons , 1998, Nature Neuroscience.
[27] P. Calabresi,et al. Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na+/K+ ATPase , 1995, The European journal of neuroscience.
[28] C. Cepeda,et al. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. , 1998, Journal of neurophysiology.
[29] P. Brundin,et al. Synaptic dysfunction in Huntington’s disease: a new perspective , 2005, Cellular and Molecular Life Sciences CMLS.
[30] Patrik Brundin,et al. Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.
[31] C. Cepeda,et al. Repeated Exposure to Methamphetamine Causes Long-Lasting Presynaptic Corticostriatal Depression that Is Renormalized with Drug Readministration , 2008, Neuron.
[32] R. Wightman,et al. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.
[33] C. Cepeda,et al. NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.
[34] E. Simpson,et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.
[35] Carlos Cepeda,et al. Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.
[36] J. Penney,et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.
[37] J. Isaacson,et al. GABAB-Mediated Presynaptic Inhibition of Excitatory Transmission and Synaptic Vesicle Dynamics in Cultured Hippocampal Neurons , 1997, Neuron.
[38] J. Isaacson,et al. GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. , 1997, Neuron.
[39] Carlos Cepeda,et al. Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.
[40] Roger L Albin,et al. Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[41] B. Harper. Huntington Disease , 2005, Journal of the Royal Society of Medicine.
[42] R. Albin,et al. Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers , 2001, Synapse.
[43] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[44] G. Hardingham,et al. The Dichotomy of NMDA Receptor Signaling , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[45] M. Chesselet,et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.
[46] P. Garris,et al. Sub-second changes in accumbal dopamine during sexual behavior in male rats , 2001, Neuroreport.
[47] H. Haas,et al. Differential modulation of AMPA receptors by cyclothiazide in two types of striatal neurons , 2000, The European journal of neuroscience.
[48] M. Mayer,et al. Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants. , 1994, Molecular pharmacology.
[49] Timothy H Murphy,et al. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. , 2004, Journal of neurophysiology.
[50] S. W. Davies,et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[51] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[52] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[53] J. Penney,et al. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.
[54] M. Hayden,et al. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.
[55] C. Nicholson,et al. Amphetamine Distorts Stimulation-Dependent Dopamine Overflow: Effects on D2 Autoreceptors, Transporters, and Synaptic Vesicle Stores , 2001, The Journal of Neuroscience.
[56] B. Sakmann,et al. Imaging Synaptic Activity in Intact Brain and Slices with FM1-43 in C. elegans, Lamprey, and Rat , 1999, Neuron.
[57] Marian DiFiglia,et al. Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.
[58] E. Richfield,et al. Reduced expression of preproenkephalin in striatal neurons from huntington's disease patients , 1995, Annals of neurology.
[59] D. Sibley,et al. Striatal neurochemical changes in transgenic models of Huntington's disease , 2002, Journal of neuroscience research.
[60] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[61] R. Palmiter,et al. Dopamine Modulates Release from Corticostriatal Terminals , 2004, The Journal of Neuroscience.
[62] Max Kleiman-Weiner,et al. Differential electrophysiological properties of dopamine D1 and D2 receptor‐containing striatal medium‐sized spiny neurons , 2008, The European journal of neuroscience.
[63] Carlos Cepeda,et al. The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.
[64] Steven A. Siegelbaum,et al. Visualization of changes in presynaptic function during long-term synaptic plasticity , 2001, Nature Neuroscience.
[65] K. Svoboda,et al. Two-photon imaging in living brain slices. , 1999, Methods.
[66] Scott H Chandler,et al. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. , 2005, Journal of neurophysiology.
[67] J. Bargas,et al. Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[68] L. Raymond,et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease , 2006, Neurobiology of Disease.